Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CSF-1 and IL-34 drive distinct microglial programs in the brain tissue

ABSTRACT: Bulk RNA sequencing of FACS sorted primary murine microglia from WT mixed glial cultures isolated from P2-3 forebrain and cerebellum, stimulated with either IL-34 or CSF-1

ORGANISM(S): Mus musculus

PROVIDER: GSE133360 | GEO | 2019/06/27

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

CSF-1 and IL-34 drive distinct microglial programs in the brain tissue

Project description:CSF-1 and IL-34 drive distinct microglial programs in the brain tissue

| PRJNA551258 | ENA

Disruption of CSF-1R signaling affects cerebellar and forebrain homeostasis

Project description:Ultra low input sequencing of FACS sorted primary murine microglia from CSF-1 or IL-34 deficient forebrain and cerebella, at P8 and 9 weeks

2019-06-27 | GSE133362 | GEO

Microglial homeostasis requires balanced CSF-1/CSF-2 receptor signaling

Project description:Microglial homeostasis requires balanced CSF-1/CSF-2 receptor signaling

| PRJNA601776 | ENA

Microglial homeostasis requires balanced CSF-1/CSF-2 receptor signaling

Project description:ALSP is a CSF1R-deficiency dementia associated with increased CSF2 expression Monoallelic deletion of Csf2 rescues most behavioral deficits and histopathological changes in Csf1r+/- mice by preventing microgliosis and eliminating most microglial transcriptomic alterations, including those indicative of oxidative stress and demyelination Elevation of Csf2 transcripts and of several CSF-2 downstream targets in the brains of ALSP patients demonstrates that the mechanisms identified in the mouse model are functional in man. Our data provide new insights into the mechanisms underlying ALSP and identify CSF-2 as a therapeutic target.

2020-01-17 | GSE143823 | GEO

RNA-seq analysis of αPD-1 treatment outcomes in IL-34 expressing or not expressing CT26 cell line

Project description:Interleukin-34 (IL-34) is an alternative ligand to colony-stimulating factor-1 (CSF-1) for the CSF-1 receptor that acts as a key regulator of monocyte/macrophage lineage. In this study, we show that cancer cells-derived IL-34 mediates resistance to immune checkpoint blockade regardless of CSF-1 existence. In a therapeutic study of a programmed death-1 and cytotoxic T-lymphocyte-associated antigen-4 blocking monoclonal antibody, the expression of IL-34 in tumors was accompanied with limited benefits compared to IL-34 non-expressing tumors in various murine cancer models. Consistent with its immunosuppressive characteristics, the expression of IL-34 in tumors correlates with decreased frequencies of cellular (such as CD8+ and CD4+ T cells) and molecular (including various cytokines and chemokines) effectors at the tumor microenvironment. In addition, IL-34 blockade expands the M1-macrophage population. Then, a neutralizing antibody against IL-34 helped to reverse these effects and improved the therapeutic effects of the immune checkpoint blockade in combinatorial therapeutic models, including a patient-derived xenograft model of primary lung adenocarcinoma. Collectively, we revealed that tumor-derived IL-34 inhibits the efficacy of immune checkpoint blockade and proposed the utility of IL-34 blockade as a new strategy for cancer therapy.

2020-09-30 | GSE157602 | GEO

CSF

Project description:CSF

| PRJEB14301 | ENA

Burkholderia thailandensis 34 strain:34

Project description:Burkholderia thailandensis 34 strain:34 Genome sequencing

| PRJNA178704 | ENA

csf

Project description:csf Raw sequence reads

| PRJNA1079012 | ENA

Disruption of CSF-1R signaling affects cerebellar and forebrain homeostasis

Project description:Disruption of CSF-1R signaling affects cerebellar and forebrain homeostasis